|
|||||
|
|
Interferons beta have vasoconstrictive and procoagulant effects: A woman who developed livedo reticularis and Raynaud phenomenon in association with interferon beta treatment for multiple sclerosis |
|
| Authors: | Uroš Rot Alenka Horvat Ledinek |
| Affiliation: | 1. MS Center Dresden, Center of Clinical Neuroscience, Department of Neurology, University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany;2. Centre for Ophthalmology, Eberhard-Karl-University Tuebingen, Tuebingen, Germany;1. Buffalo Neuroimaging Analysis Center, Department of Neurology, State University of New York, Buffalo, USA;2. Department of Neurology, Referral Centre for Demyelinating Disease of the Central Nervous System, University Hospital Centre Zagreb, Zagreb, Croatia;3. The Jacobs Neurological Institute, Department of Neurology, University at Buffalo, State University of New York, Buffalo, USA;4. Department of Pharmaceutical Sciences, State University of New York, Buffalo, USA;1. Department of Otorhinolaryngology, General Hospital Karlovac, A. Stampara 3, 47000 Karlovac, Croatia;2. Department of Neurology, General Hospital Karlovac, Karlovac, Croatia;3. SLP, Polyclinic SUVAG, Karlovac, Croatia |
| Abstract: | A 31-year-old woman with MS developed livedo reticularis and secondary Raynaud phenomenon 2.5 years after introduction of interferon beta-1b. The symptoms disappeared after withdrawal of the drug. Livedo reticularis and Raynaud phenomenon as well as pulmonary arterial hypertension, venous sinus thrombosis, pulmonary embolism and renal thrombotic microangiopathy have all been described in association with interferon beta therapy. These complications strongly suggest that type I interferons have vasoconstrictive and procoagulant effects with potentially serious systemic complications. |
| Keywords: | Multiple sclerosis Interferon beta Side effects Raynaud phenomenon Livedo reticularis |
| 本文献已被 ScienceDirect 等数据库收录！ | |